Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

PGDx elio™ tissue complete assay

FDA Approved
Related tests:
PGDx elio™ tissue complete is a comprehensive, in-vitro diagnostic, next generation sequencing (NGS) assay that identifies key genomic alterations and guideline supported biomarkers in solid tumors using a 500+ gene panel. PGDx elio™ tissue complete is the industry’s first and only NGS diagnostic kit for comprehensive tumor profiling that is FDA-cleared for use in labs across the country. This assay identifies somatic mutations with high accuracy and sensitivity, providing information on single nucleotide variants, insertions/deletions (indels), amplifications, translocations, microsatellite instability (MSI) status and tumor mutation burden (TMB) to qualified healthcare professionals for use in accordance with NCCN guidelines.
Solid Tumor
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), GATA6 (GATA Binding Protein 6), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), MSI (Microsatellite instability)
See More ...
Next-Generation Sequencing (NGS)